Effective Detection and Monitoring of Glioma Using [
[18F]FPIA PET imaging
fatty acid metabolism
glioma
proliferation
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
13 Jul 2021
13 Jul 2021
Historique:
received:
10
05
2021
revised:
25
06
2021
accepted:
09
07
2021
entrez:
6
8
2021
pubmed:
7
8
2021
medline:
7
8
2021
Statut:
epublish
Résumé
Reprogrammed cellular metabolism is a cancer hallmark. In addition to increased glycolysis, the oxidation of acetate in the citric acid cycle is another common metabolic phenotype. We have recently developed a novel fluorine-18-labelled trimethylacetate-based radiotracer, [ We evaluated the potential of [ Longitudinal PET imaging showed gradual increase in [ Our findings support the use of [
Sections du résumé
BACKGROUND
BACKGROUND
Reprogrammed cellular metabolism is a cancer hallmark. In addition to increased glycolysis, the oxidation of acetate in the citric acid cycle is another common metabolic phenotype. We have recently developed a novel fluorine-18-labelled trimethylacetate-based radiotracer, [
METHODS
METHODS
We evaluated the potential of [
RESULTS
RESULTS
Longitudinal PET imaging showed gradual increase in [
CONCLUSIONS
CONCLUSIONS
Our findings support the use of [
Identifiants
pubmed: 34356874
pii: biomedicines9070811
doi: 10.3390/biomedicines9070811
pmc: PMC8301305
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Medical Research Council
ID : MR/T029226/1
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C2536/A16584
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N020782/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0701159
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 25887
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 16584
Pays : United Kingdom
Références
Biochim Biophys Acta. 2011 Jun;1807(6):726-34
pubmed: 21692241
Oncotarget. 2017 Feb 28;8(9):14860-14875
pubmed: 28118603
Nucl Med Rev Cent East Eur. 2002;5(2):127-30
pubmed: 14600871
J Nucl Med. 2008 Feb;49(2):327-34
pubmed: 18199615
Am J Physiol Renal Physiol. 2019 Dec 1;317(6):F1669-F1679
pubmed: 31682169
Biochem Pharmacol. 1987 Oct 15;36(20):3405-9
pubmed: 3675603
Cell. 2014 Dec 18;159(7):1603-14
pubmed: 25525878
Br J Cancer. 2010 May 25;102(11):1555-77
pubmed: 20502460
Chem Biol Interact. 2009 Aug 14;180(3):472-7
pubmed: 19539806
Endocrinology. 2020 Feb 1;161(2):
pubmed: 31900483
Neuro Oncol. 2017 Jan;19(1):43-54
pubmed: 27365097
Nat Rev Cancer. 2016 Nov;16(11):718-731
pubmed: 27562463
J Nucl Med. 2014 Sep;55(9):1506-12
pubmed: 25012458
J Nucl Med. 2006 May;47(5):776-82
pubmed: 16644747
Neuro Oncol. 2016 Oct 1;18(suppl_5):v1-v75
pubmed: 28475809
J Nucl Med. 2015 Aug;56(8):1239-45
pubmed: 26045312
Pharmacol Rev. 2002 Dec;54(4):589-98
pubmed: 12429869
Nat Rev Cancer. 2016 Nov;16(11):708-717
pubmed: 27562461
NMR Biomed. 2012 Nov;25(11):1234-44
pubmed: 22419606
Mol Imaging Biol. 2015 Aug;17(4):529-38
pubmed: 25561013
Br J Cancer. 2008 Dec 16;99(12):2037-43
pubmed: 19034272
Neuro Oncol. 2013 Mar;15(3):341-51
pubmed: 23335162
PLoS Biol. 2018 Mar 29;16(3):e2003782
pubmed: 29596410
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
PLoS One. 2017 May 17;12(5):e0176528
pubmed: 28520730
Eur J Nucl Med Mol Imaging. 2012 Jun;39(6):1021-9
pubmed: 22491781
JAMA. 2013 Nov 6;310(17):1842-50
pubmed: 24193082
AJNR Am J Neuroradiol. 2011 Dec;32(11):1978-85
pubmed: 21393407
Curr Neurol Neurosci Rep. 2016 Feb;16(2):17
pubmed: 26759318
Neuro Oncol. 2012 Nov;14 Suppl 5:v1-49
pubmed: 23095881
Eur J Nucl Med Mol Imaging. 2020 Oct;47(11):2549-2561
pubmed: 32123971
Clin Cancer Res. 2019 May 1;25(9):2874-2886
pubmed: 30670496
Cancer Lett. 2015 Jan 28;356(2 Pt A):211-6
pubmed: 24569091
Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:663-687
pubmed: 29309257
Drug Metab Pharmacokinet. 2008;23(4):293-303
pubmed: 18762717
J Neurochem. 2021 Mar;156(5):642-657
pubmed: 32654140